Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyaluronidase for Oral Microstomia in Sclerosing Skin Disease
NCT04656704Phase 1Withdrawn
- Sponsor
- Brigham and Women's Hospital
- Start
- Jan 2020
- Primary completion
- Jan 2022
- Modality
- Therapeutic Enzymes
01
Overview
Phase 1, open-label, single-arm trial of hyaluronidase in microstomia, sponsored by Brigham and Women's Hospital. Primary endpoint: Change of oral aperture at the largest diameter at Week 24. Planned start Jan 2020; status: withdrawn.
02
Drugs
hyaluronidase
03
Conditions
microstomia
Beyond the preview
Go deeper on NCT04656704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04656704.